<i>EGFR</i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with <i>EGFR</i> T790M Mutation
Abstract
The non-small cell lung cancer with activating epidermal growth factor receptor (EGFR) mutation eventually acquires resistant to either first or second-generation EGFR tyrosine kinase inhibitor (TKI). As the following option, targeting EGFR T790M with third-generation EGFR TKI is now established as a standard treatment option. In this study, we are reporting the first case of resistance mechanism to the novel third-generation EGFR TKI,...
Paper Details
Title
<i>EGFR</i> C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with <i>EGFR</i> T790M Mutation
Published Date
Jun 22, 2020
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History